In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

uniQure NV

www.uniqure.com

Latest From uniQure NV

NIH Ends Gene Therapy Trial Reporting Requirements In Reg Streamlining Move

Trial protocols, annual reports, and adverse event reports on gene therapies will only go to US FDA under now-finalized amendments, a sign that the product category is maturing and can be regulated like other drugs and biologics.

Regenerative Medicine Research and Development Strategies

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies

UniQure Has High HOPE For Hemophilia B Gene Therapy

The Dutch company's update on AMT-061 and the initiation of a pivotal trial called HOPE-B of around 50 patients could put the product in pole position to be the first gene therapy on the market for the severe orphan blood clotting disorder.

Blood & Coagulation Disorders Regenerative Medicine

UniQure Hemophilia B Gene Therapy AMT-061 Has Early Phase IIb Success

Early positive data from a Phase IIb dose-confirmation study showed AMT-061 achieved and sustained therapeutic levels of Factor IX (FIX) activity in all three participating patients at six weeks after a single administration of the investigational AAV5-based gene therapy.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • uniQure BV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • uniQure NV
  • Senior Management
  • Matthew Kapusta, CEO
    Sander van Deventer, MD, PhD, CSO
    Jonathan Garen, CBO
    Scott McMillan, PhD, COO
    Robert Gut, MD, PhD, CMO
  • Contact Info
  • uniQure NV
    Phone: 20 240 6000
    P.O. Box 22506 Amsterdam, 1100 DA
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register